

From: [REDACTED]
Sent: Fri May 12 2006 16:45:57 EDT
To: ratna lingamaneni/cambridge/biogen@biogenidec;
CC: bg-12 program team: [REDACTED]
[REDACTED]
[REDACTED];minhua
yang/cambridge/biogen@biogenidec; [REDACTED]
[REDACTED];
Subject: Re: BG12 IND - response to clinical hold submitted (5/12/06)

Congratulations team! I know this was a far more significant effort than we thought at first glance and we had our share of challenges. I appreciate that we held together as a team and many went way above and beyond to get this done quickly. Many thanks for your efforts!

[REDACTED]

[REDACTED]
Sr. Manager, Clinical Development
Medical Research, Immunology
Biogen Idec, Inc.
Cambridge, MA 02142

[REDACTED]
[REDACTED]
[REDACTED]

Ratna Lingamaneni/Cambridge/Biogen
12-May-2006 04:20 PM
Message Size: 2.9 KB

To
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED]
[REDACTED] Minhua Yang/Cambridge/Biogen@BiogenIdec

cc
[REDACTED]
[REDACTED]
Subject

BG12 IND - response to clinical hold submitted (5/12/06)

Dear All,

The BG12 IND - RESPONSE TO CLINICAL HOLD was submitted to the FDA today. Thank you to the many people who contributed to this submission.

Please let me know if you have any questions.

-Ratna